Withdrawing off-label antipsychotics in people with intellectual disabilities: why does it fail?

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON21687

Enrollment

122

Registered

2018-05-25

Start date

2019-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antipsychotics, intellectual disabilities Antipsychotica, verstandelijke beperking

Interventions

Risperidone or pipamperone tablets will be replaced by liquid form. All participants receive a dosage scheme: -25% of the original dosage every 4 weeks in the discontinuation group, dosage remains una

Eligibility

Inclusion criteria

Inclusion criteria: Adults with ID (IQ 1 year for behavioral problems. Participants are living (=>ZZP4) in three participating ID care organizations of the HA-ID consort.

Exclusion criteria

Exclusion criteria: Diagnosis of psychosis, dementia, schizophrenia, psychotic disorder NOS, delirium, failed attempt to withdraw AP 1 AP drug

Design outcomes

Secondary

Measure	Time frame
Behavior Psychiatric disorders Sleep problems Side effects / withdrawal symptoms	—

Primary

Measure	Time frame
The percentage of participants completing the protocol in the “discontinuation group” (gradual decline of AP dose) compared to the “control group” (continuing AP dose).	—

Contacts

Public ContactD.A.M. Maes-Festen

Erasmus MC

d.maes-festen@erasmusmc.nl0107032123

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)